E.g., 29/11/2020
E.g., 29/11/2020
PreviousNext

bioMérieux announces the expansion of the CE marking of its molecular biology ARGENE® SARS-CoV-2 diagnostic test to include saliva specimens.  

Marcy l’Etoile, France – November 16, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, has announced the expansion of its ARGENE® range for the detection of SARS-CoV-2. As a complement to nasopharyngeal swab specimens, the singleplex SARS-CoV-2 R-GENE® real-time PCR test may now be used on saliva and oropharyngeal (throat) swab specimens for the detection of the virus that causes COVID-19. This development helps optimize laboratory workflows.

16 November, 2020

The CE-marked SARS-CoV-2 R-GENE® test covers the above three sample types. This allows bioMérieux to address the recommendation issued by the French National Authority for Health (HAS) on September 18, 2020, which encourages the preferential use of saliva swabs to test symptomatic...

bioMérieux – Third-Quarter 2020 Business Review  

22 October, 2020

  • Organic growth of 19.4% at constant exchange rates and scope of consolidation over the first nine months of the year:
    • €2,266 million in sales
    • Up 17.5% as reported
...

AMSP partners with bioMérieux to facilitate supply of high-quality COVID-19 diagnostics

08 October, 2020

bioMérieux and the Africa Medical Supplies Platform (AMSP), have announced a new partnership to facilitate the supply of high-quality diagnostic solutions from the bioMérieux Pandemic Response Portfolio to African Union Member States.

The AMSP portal is an online marketplace that enables...

First-Half 2020 Results

02 September, 2020

  • Organic sales growth of 15.7% in first-half 2020:
    • €1,476 million in sales
    • Up 15.8% as reported
  • As expected, a mixed sales performance, with faster momentum in molecular biology solutions contrasting with a...

Launch of BIOFIRE® MYCOPLASMA test for mycoplasma detection in biopharmaceutical products

16 July, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, has announced the launch of BIOFIRE® MYCOPLASMA, an innovative test for mycoplasma detection in pharmaceutical products used for biotherapeutics (antibodies, hormones, cell and gene therapies, etc.),...

BIOFIRE® Respiratory Panel 2.1 plus with SARS-CoV-2 is CE marked

15 July, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that the BIOFIRE® Respiratory Panel 2.1 plus (RP2.1plus) is CE marked. The BIOFIRE® Respiratory Panel 2.1 plus (RP2.1plus) tests for 23...

Second-Quarter 2020 Business Performance Preannouncement

09 July, 2020

In light of the withdrawal of its annual objectives, bioMérieux, a world leader in the field of in vitro diagnostics, today announced preliminary quarterly information about its business activity ending June 30, 2020.

  • Organic growth of 15.7...

bioMérieux issues a €200 million Euro PP bond  

29 June, 2020

Marcy l’Étoile (France) - June 29, 2020 – bioMérieux, a global leader in the field of in vitro diagnostics, announces that it has successfully issued today a €200 million Euro PP new debt with a top-tier European institutional...

CE marking of bioMérieux serology tests for SARS-CoV-2 on VIDAS®

21 May, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, today announced the CE marking of VIDAS® anti-SARS-CoV-2 serology tests to detect...

Information concerning 2019 dividend and the bioMérieux  General Shareholders’ Meeting 

19 May, 2020

The Board of Directors of bioMérieux met today and decided to hold the annual General Shareholders’ Meeting behind closed doors at the bioMérieux registered office on June 30, 2020. During this meeting, it will recommend reducing the 2019 dividend in order to support initiatives in the...

PreviousNext